retatrutide phase 2 nejm weight loss 48 weeks triple agonist vs Mounjaro Retatrutide: The New Triple-Agonist Weight

Clinical cancer research: an official journal of the American Association for Cancer Research

Switching goals: Weight-focused options are being considered

Blood sugar control that extends beyond diabetes management Tirzepatide received its initial approval for type 2 diabetes management, and its glucose-lowering effects remain among its most potent actions

The DELIVER trial randomized 6,263 patients with symptomatic HF, 74% of whom had NYHA class II symptoms, either with HF with moderately reduced ejection fraction (HFmrEF

This can lead to eating less and consuming fewer calories, which can help with weight loss